Cargando…

Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis

BACKGROUND: Current evidence suggests that roflumilast is efficacious in treating COPD, especially in preventing the acute exacerbation of COPD. OBJECTIVES: This study was designed to evaluate the clinical effects and safety of roflumilast in the treatment of stable COPD using randomized clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Lianfang, Dai, Xuan, Yang, Meng, Cai, Qiling, Shao, Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934559/ https://www.ncbi.nlm.nih.gov/pubmed/27418821 http://dx.doi.org/10.2147/COPD.S106370

Ejemplares similares

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
por: Zhang, Xiaoli, et al.
Publicado: (2018)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
por: Puhan, Milo A., et al.
Publicado: (2015)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials
por: Jafari Andarian, Saeideh, et al.
Publicado: (2016)

New therapeutic options in the management of COPD – focus on roflumilast
por: Antoniu, Sabina Antonela
Publicado: (2011)

Does roflumilast induce phagocytic activity in COPD patients?
por: Ghosh, Baishakhi, et al.
Publicado: (2015)

A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers
por: Matencio, Adrián, et al.
Publicado: (2019)

The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD
por: Williams, Dennis
Publicado: (2020)

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
por: Park, Tai Sun, et al.
Publicado: (2019)

Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD
por: Reddy, Aravind T, et al.
Publicado: (2020)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
por: Watz, Henrik, et al.
Publicado: (2018)

Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
por: Liu, Dong-yang, et al.
Publicado: (2018)

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
por: Rennard, Stephen I, et al.
Publicado: (2011)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease
por: Wagner, Linda Timm, et al.
Publicado: (2005)

Effectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
por: Naseem, Sumbal, et al.
Publicado: (2022)

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
por: Calverley, Peter MA, et al.
Publicado: (2012)

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist
por: Milara, Javier, et al.
Publicado: (2015)

Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population
por: Moll, Keran, et al.
Publicado: (2015)

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA
por: Kardos, Peter, et al.
Publicado: (2018)

Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?
por: Shah, Chirag A.
Publicado: (2020)

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)
por: Gyldenløve, Mette, et al.
Publicado: (2023)

Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast
por: Barnes, Neil C, et al.
Publicado: (2014)

Roflumilast partially reverses smoke-induced mucociliary dysfunction
por: Schmid, Andreas, et al.
Publicado: (2015)

Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy
por: Ring, Hans Christian, et al.
Publicado: (2022)

Safety and efficacy of tyrosine kinase inhibitors for the treatment of multiple sclerosis: A systematic review and meta-analysis from randomized controlled trials
por: Yan, Zeya, et al.
Publicado: (2022)

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
por: Gauvreau, Gail M, et al.
Publicado: (2011)

Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway
por: Xu, Wan, et al.
Publicado: (2021)

Safety, tolerability and risk benefit analysis of tiotropium in COPD
por: Oba, Yuji, et al.
Publicado: (2008)

Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice
por: Martorana, Piero A, et al.
Publicado: (2008)

Rapid Liquid Chromatographic Method for the Determination of Roflumilast in the Presence of Degradation Products
por: Barhate, V D, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_96rn0c4q33ind0139ffgu3uoia